Related references
Note: Only part of the references are listed.Changes in metabolic parameters in patients with severe mental illness over a 10-year period: A retrospective cohort study
Adrian H. Heald et al.
AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY (2017)
Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis
Jackie Curtis et al.
EARLY INTERVENTION IN PSYCHIATRY (2016)
Patients with psychiatric comorbidity can safely undergo bariatric surgery with equivalent success
Hans F. Fuchs et al.
SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES (2016)
Metformin as firstline treatment for type 2 diabetes: are we sure?
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
PRACTICE POINTER Primary care management of patients after weight loss surgery
Michael Moore et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
THERAPEUTICS Drugs for smoking cessation
Jamie Hartmann-Boyce et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Metformin as firstline treatment for type 2 diabetes: are we sure?
Remy Boussageon et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
PRACTICE POINTER Primary care management of patients after weight loss surgery
Michael Moore et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
THERAPEUTICS Drugs for smoking cessation
Jamie Hartmann-Boyce et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Weight gain and obesity in schizophrenia: epidemiology, pathobiology, and management
P. Manu et al.
ACTA PSYCHIATRICA SCANDINAVICA (2015)
Pragmatic Replication Trial of Health Promotion Coaching for Obesity in Serious Mental Illness and Maintenance of Outcomes
Stephen J. Bartels et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
The STRIDE Weight Loss and Lifestyle Intervention for Individuals Taking Antipsychotic Medications: A Randomized Trial
Carla A. Green et al.
AMERICAN JOURNAL OF PSYCHIATRY (2015)
The changing face of diabetes in youth: lessons learned from studies of type 2 diabetes
Tamara S. Hannon et al.
YEAR IN DIABETES AND OBESITY (2015)
Long-Acting Injectable vs Oral Risperidone for Schizophrenia and Co-Occurring Alcohol Use Disorder: A Randomized Trial
Alan I. Green et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Importance of Early Weight Changes to Predict Long-Term Weight Gain During Psychotropic Drug Treatment
Frederik Vandenberghe et al.
JOURNAL OF CLINICAL PSYCHIATRY (2015)
Cardiovascular risks and benefits of moderate and heavy alcohol consumption
Joaquim Fernandez-Sola
NATURE REVIEWS CARDIOLOGY (2015)
Bariatric surgery: a viable treatment option for patients with severe mental illness
Sarah R. Shelby et al.
SURGERY FOR OBESITY AND RELATED DISEASES (2015)
Screening for the metabolic side effects of antipsychotic medication: findings of a 6-year quality improvement programme in the UK
T. R. E. Barnes et al.
BMJ OPEN (2015)
Smoking cessation and reduction in people with chronic mental illness
Jennifer W. Tidey et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts
Craig S. Knott et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Smoking cessation and reduction in people with chronic mental illness
Jennifer W. Tidey et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts
Craig S. Knott et al.
BMJ-BRITISH MEDICAL JOURNAL (2015)
Premature Mortality Among Adults With Schizophrenia in the United States
Mark Olfson et al.
JAMA PSYCHIATRY (2015)
Cardiovascular Risk Prediction Models for People With Severe Mental Illness Results From the Prediction and Management of Cardiovascular Risk in People With Severe Mental Illnesses (PRIMROSE) Research Program
David P. J. Osborn et al.
JAMA PSYCHIATRY (2015)
Diabetes mellitus and severe mental illness: mechanisms and clinical implications
Richard I. G. Holt et al.
NATURE REVIEWS ENDOCRINOLOGY (2015)
Metabolic syndrome in people with schizophrenia: a review
MARC DE HERT et al.
World Psychiatry (2015)
Bespoke smoking cessation for people with severe mental ill health (SCIMITAR): a pilot randomised controlled trial
Simon Gilbody et al.
LANCET PSYCHIATRY (2015)
Melatonin attenuates antipsychotic metabolic effects: an eight-week randomized, double-blind, parallel-group, placebo-controlled clinical trial
Francisco Romo-Nava et al.
BIPOLAR DISORDERS (2014)
Assessment and treatment of physical health problems among people with schizophrenia: national cross-sectional study
Mike J. Crawford et al.
BRITISH JOURNAL OF PSYCHIATRY (2014)
Smoking and Long-Term Risk of Type 2 Diabetes: The EPIC-InterAct Study in European Populations
Annemieke M. W. Spijkerman et al.
DIABETES CARE (2014)
Quality of prescribing for schizophrenia: Evidence from a national audit in England and Wales
Maxine X. Patel et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2014)
Association of ADRA2A and MTHFR gene polymorphisms with weight loss following antipsychotic switching to aripiprazole or ziprasidone
Siti Norsyuhada Roffeei et al.
HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL (2014)
An Exploratory Randomized Controlled Study of a Healthy Living Intervention in Early Intervention Services for Psychosis: the INTERvention to Encourage ACTivity, Improve Diet, and Reduce Weight Gain (INTERACT) Study
Karina Lovell et al.
JOURNAL OF CLINICAL PSYCHIATRY (2014)
Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: Randomized double-blind placebo-controlled study
Amirhossein Modabbernia et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2014)
Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
Rury R. Holman et al.
LANCET (2014)
The Effects of Lifestyle Interventions on (Long-Term) Weight Management, Cardiometabolic Risk and Depressive Symptoms in People with Psychotic Disorders: A Meta-Analysis
Jojanneke Bruins et al.
PLOS ONE (2014)
Continuing Weight-Loss Effect after Topiramate Discontinuation in Obese Persons with Schizophrenia: a Pilot Open-Label Study
C. -S. Liang et al.
PHARMACOPSYCHIATRY (2014)
Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis
Yuya Mizuno et al.
SCHIZOPHRENIA BULLETIN (2014)
Cardiometabolic Risk in Patients With First-Episode Schizophrenia Spectrum Disorders Baseline Results From the RAISE-ETP Study
Christoph U. Correll et al.
JAMA PSYCHIATRY (2014)
Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia
X. Fan et al.
ACTA PSYCHIATRICA SCANDINAVICA (2013)
Metformin for Weight Loss and Metabolic Control in Overweight Outpatients With Schizophrenia and Schizoaffective Disorder
L. Fredrik Jarskog et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Sustained Weight Loss After Treatment With a Glucagon-Like Peptide-1 Receptor Agonist in an Obese Patient With Schizophrenia and Type 2 Diabetes
Pelle L. Ishoy et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
The effect of bariatric surgery on psychiatric course among patients with bipolar disorder
Ameena T. Ahmed et al.
BIPOLAR DISORDERS (2013)
Management of smoking reduction and cessation in inpatients with schizophrenia: impact of electronic cigarettes
G. Minutolo et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2013)
Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial
W. Wolfgang Fleischhacker et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2013)
Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study
Stephen M. Stahl et al.
JOURNAL OF CLINICAL PSYCHIATRY (2013)
Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents
Shamail Mahmood et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2013)
Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
Stefan Leucht et al.
LANCET (2013)
A Behavioral Weight-Loss Intervention in Persons with Serious Mental Illness
Gail L. Daumit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Clinically Significant Improved Fitness and Weight Loss Among Overweight Persons With Serious Mental Illness
Stephen J. Bartels et al.
PSYCHIATRIC SERVICES (2013)
Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination
Michael Poyurovsky et al.
PSYCHOPHARMACOLOGY (2013)
Is the Prevalence of Metabolic Syndrome and Metabolic Abnormalities Increased in Early Schizophrenia? A Comparative Meta-Analysis of First Episode, Untreated and Treated Patients
Alex J. Mitchell et al.
SCHIZOPHRENIA BULLETIN (2013)
The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: A randomized, double-blind, placebo-controlled clinical trial
Ahmad Ghanizadeh et al.
SCHIZOPHRENIA RESEARCH (2013)
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects
Alkomiet Hasan et al.
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY (2013)
A meta-analysis of cardio-metabolic abnormalities in drug naive, first-episode and multi-episode patients with schizophrenia versus general population controls
Davy Vancampfort et al.
WORLD PSYCHIATRY (2013)
The gap in life expectancy from preventable physical illness in psychiatric patients in Western Australia: retrospective analysis of population based registers
David Lawrence et al.
BMJ-BRITISH MEDICAL JOURNAL (2013)
Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth
William V. Bobo et al.
JAMA PSYCHIATRY (2013)
Psychosocial interventions for people with both severe mental illness and substance misuse
Glenn E. Hunt et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Metformin for Treatment of Antipsychotic-Induced Amenorrhea and Weight Gain in Women With First-Episode Schizophrenia: A Double-Blind, Randomized, Placebo-Controlled Study
Ren-Rong Wu et al.
AMERICAN JOURNAL OF PSYCHIATRY (2012)
Zonisamide for Weight Reduction in Obese Adults A 1-Year Randomized Controlled Trial
Kishore M. Gadde et al.
ARCHIVES OF INTERNAL MEDICINE (2012)
Long-Term Safety, Tolerability, and Weight Loss Associated With Metformin in the Diabetes Prevention Program Outcomes Study
George A. Bray et al.
DIABETES CARE (2012)
The heart of the matter: cardiometabolic care in youth with psychosis
Jackie Curtis et al.
EARLY INTERVENTION IN PSYCHIATRY (2012)
Comparison of Long-Term (At Least 24 Weeks) Weight Gain and Metabolic Changes Between Adolescents and Adults Treated with Olanzapine
Ludmila A. Kryzhanovskaya et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2012)
Assessment of Treatment Algorithms Including Amantadine, Metformin, and Zonisamide for the Prevention of Weight Gain With Olanzapine: A Randomized Controlled Open-Label Study
Vicki Poole Hoffmann et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
Tobacco Use Before, At, and After First-Episode Psychosis: A Systematic Meta-Analysis
Nicholas Myles et al.
JOURNAL OF CLINICAL PSYCHIATRY (2012)
BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP
A. R. Lingford-Hughes et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2012)
Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications
T. A. P. Lett et al.
MOLECULAR PSYCHIATRY (2012)
The Role of Primary Care in Service Provision for People with Severe Mental Illness in the United Kingdom
Siobhan Reilly et al.
PLOS ONE (2012)
Acute and maintenance effects of non-pharmacologic interventions for antipsychotic associated weight gain and metabolic abnormalities: A meta-analytic comparison of randomized controlled trials
Jacqueline Caemmerer et al.
SCHIZOPHRENIA RESEARCH (2012)
Predicting the 10 year risk of cardiovascular disease in the United Kingdom: independent and external validation of an updated version of QRISK2
Gary S. Collins et al.
BRITISH MEDICAL JOURNAL (2012)
Pharmacogenetic Aspects of Antipsychotic Drug-induced Weight Gain - A Critical Review
Gavin P. Reynolds
Clinical Psychopharmacology and Neuroscience (2012)
Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials
Samir Kumar Praharaj et al.
THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2012)
A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP)
T. Scott Stroup et al.
AMERICAN JOURNAL OF PSYCHIATRY (2011)
Systematic Review of Early Cardiometabolic Outcomes of the First Treated Episode of Psychosis
Debra L. Foley et al.
ARCHIVES OF GENERAL PSYCHIATRY (2011)
Weight Gain and Metabolic Risks Associated with Antipsychotic Medications in Children and Adolescents
Lawrence Maayan et al.
JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY (2011)
Orlistat in Clozapine- or Olanzapine-Treated Patients With Overweight or Obesity: A 16-Week Open-Label Extension Phase and Both Phases of a Randomized Controlled Trial
Evgueni Tchoukhine et al.
JOURNAL OF CLINICAL PSYCHIATRY (2011)
Effects of the Cannabinoid-1 Receptor Antagonist Rimonabant on Psychiatric Symptoms in Overweight People With Schizophrenia A Randomized, Double-Blind, Pilot Study
Deanna L. Kelly et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2011)
Open adjunctive ziprasidone associated with weight loss in obese and overweight bipolar disorder patients
Po W. Wang et al.
JOURNAL OF PSYCHIATRIC RESEARCH (2011)
Topiramate dose effects on cognition A randomized double-blind study
D. W. Loring et al.
NEUROLOGY (2011)
Views of Young People in Early Intervention Services for First-Episode Psychosis in England
Helen Lester et al.
PSYCHIATRIC SERVICES (2011)
Effect of aripiprazole augmentation of clozapine in schizophrenia: A double-blind, placebo-controlled study
Maria Rosaria A. Muscatello et al.
SCHIZOPHRENIA RESEARCH (2011)
Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care
Marc De Hert et al.
WORLD PSYCHIATRY (2011)
Assessment of adverse effects in clinical studies of antipsychotic medication: survey of methods used
Alison Pope et al.
BRITISH JOURNAL OF PSYCHIATRY (2010)
Zonisamide-Induced Weight Loss in Schizophrenia: Case Series
Jaewon Yang et al.
CLINICAL NEUROPHARMACOLOGY (2010)
Effects of adjunctive treatment with aripiprazole on body weight and clinical efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial
W. Wolfgang Fleischhacker et al.
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY (2010)
Intentional Weight Loss in Overweight and Obese Patients With Severe Mental Illness: 8-Year Experience of a Behavioral Treatment Program
Richard I. G. Holt et al.
JOURNAL OF CLINICAL PSYCHIATRY (2010)
Topiramate Augmentation in Clozapine-Treated Patients With Schizophrenia Clinical and Metabolic Effects
Margaret K. Hahn et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2010)
Effectiveness of Medications Used to Attenuate Antipsychotic-Related Weight Gain and Metabolic Abnormalities: A Systematic Review and Meta-Analysis
Lawrence Maayan et al.
NEUROPSYCHOPHARMACOLOGY (2010)
Behavioural Interventions for Obese Adults with Additional Risk Factors for Morbidity: Systematic Review of Effects on Behaviour, Weight and Disease Risk Factors
Stephan U. Dombrowski et al.
OBESITY FACTS (2010)
Metabolic side effects of antipsychotic drug treatment - pharmacological mechanisms
Gavin P. Reynolds et al.
PHARMACOLOGY & THERAPEUTICS (2010)
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis
Christine Rummel-Kluge et al.
SCHIZOPHRENIA RESEARCH (2010)
Topiramate for prevention of olanzapine associated weight gain and metabolic dysfunction in schizophrenia: A double-blind, placebo-controlled trial
Preeta Kaur Narula et al.
SCHIZOPHRENIA RESEARCH (2010)
Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial
Mario Alvarez-Jimenez et al.
SCHIZOPHRENIA RESEARCH (2010)
Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problems
Anitha Mukundan et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2010)
The impact of zonisamide on weight. A clinical study in 103 patients with epilepsy
J. Wellmer et al.
ACTA NEUROLOGICA SCANDINAVICA (2009)
Prevalence of alcohol use disorders in schizophrenia - a systematic review and meta-analysis
J. Koskinen et al.
ACTA PSYCHIATRICA SCANDINAVICA (2009)
When Prevention Fails: Obesity Treatment Strategies
Louis J. Aronne et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Quality of medical care for people with and without comorbid mental illness and substance misuse: systematic review of comparative studies
Alex J. Mitchell et al.
BRITISH JOURNAL OF PSYCHIATRY (2009)
Metformin for Obesity in Children and Adolescents: A Systematic Review
Min Hae Park et al.
DIABETES CARE (2009)
Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC)
M. De Hert et al.
EUROPEAN PSYCHIATRY (2009)
Cardiometabolic Risk of Second-Generation Antipsychotic Medications During First-Time Use in Children and Adolescents
Christoph U. Correll et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Are Weight Gain and Metabolic Side Effects of Atypical Antipsychotics Dose Dependent? A Literature Review
Viktoria Simon et al.
JOURNAL OF CLINICAL PSYCHIATRY (2009)
Aripiprazole Added to Overweight and Obese Olanzapine-Treated Schizophrenia Patients
David C. Henderson et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2009)
Topiramate add-on treatment in schizophrenia: a randomised, double-blind, placebo-controlled clinical trial
H. Afshar et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2009)
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study)
Jari Tiihonen et al.
LANCET (2009)
10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study
G. A. Bray et al.
LANCET (2009)
Screening for the metabolic syndrome in community psychiatric patients prescribed antipsychotics: a quality improvement programme
T. R. E. Barnes et al.
ACTA PSYCHIATRICA SCANDINAVICA (2008)
Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study
Ren-Rong Wu et al.
AMERICAN JOURNAL OF PSYCHIATRY (2008)
Influence of 5-HT2c receptor and leptin gene polymorphisms, smoking and drug treatment on metabolic disturbances in patients with schizophrenia
Olga O. Yevtushenko et al.
BRITISH JOURNAL OF PSYCHIATRY (2008)
General cardiovascular risk profile for use in primary care - The Framingham Heart Study
Ralph B. D'Agostino et al.
CIRCULATION (2008)
Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity:: A 16-week randomized, double-blind, placebo-controlled trial
Grigori Joffe et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats
S. Snigdha et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2008)
Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder:: an open randomised clinical trial
Rene S. Kahn et al.
LANCET (2008)
The once-daily human GLP-1 analog, liraglutide, reduces olanzapine-induced weight gain and glucose intolerance
Kirsten Lykkegaard et al.
SCHIZOPHRENIA RESEARCH (2008)
Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone
Peter J. Weiden et al.
NEUROPSYCHOPHARMACOLOGY (2008)
The effects of transdermal nicotine on cognition in nonsmokers with schizophrenia and nonpsychiatric controls
Ruth S. Barr et al.
NEUROPSYCHOPHARMACOLOGY (2008)
Active smoking and the risk of type 2 diabetes - A systematic review and meta-analysis
Carole Willi et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
Diana Rucker et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
A UK audit of screening for the metabolic side effects of antipsychotics in community patients
Thomas R. E. Barnes et al.
SCHIZOPHRENIA BULLETIN (2007)
Physical activity, dietary habits and Coronary Heart Disease risk factor knowledge amongst people with severe mental illness - A cross sectional comparative study in primary care
David P. J. Osborn et al.
SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY (2007)
Long-term persistence with orlistat and sibutramine in a population-based cohort
R. Padwal et al.
INTERNATIONAL JOURNAL OF OBESITY (2007)
Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study
Julia Hippisley-Cox et al.
BMJ-BRITISH MEDICAL JOURNAL (2007)
Attenuating effect of reboxetine on appetite and weight gain in olanzapine-treated schizophrenia patients: a double-blind placebo-controlled study
Michael Poyurovsky et al.
PSYCHOPHARMACOLOGY (2007)
Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia
A. H. Barnett et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2007)
Olanzapine-induced weight gain and increased visceral adiposity is blocked by melatonin replacement therapy in rats
Murray A. Raskind et al.
NEUROPSYCHOPHARMACOLOGY (2007)
Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Research Database
David P. J. Osborn et al.
ARCHIVES OF GENERAL PSYCHIATRY (2007)
Body mass index, waist circumference and quality of life in individuals with schizophrenia
Guy Faulkner et al.
SCHIZOPHRENIA RESEARCH (2007)
Effect of topiramate on plasma concentrations of clozapine, olanzapine, risperidone, and quetiapine in patients with psychotic disorders
Gaetana Migliardi et al.
CLINICAL NEUROPHARMACOLOGY (2007)
Long-term topiramate treatment of psychotropic drug-induced weight gain: a retrospective chart review
Yasser Khazaal et al.
GENERAL HOSPITAL PSYCHIATRY (2007)
Psychotic spectrum disorders and alcohol abuse: A review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram
Ismene L. Petrakis et al.
SCHIZOPHRENIA BULLETIN (2006)
Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients:: A randomized controlled trial
Mario Alvarez-Jimenez et al.
JOURNAL OF CLINICAL PSYCHIATRY (2006)
Comorbid substance use and age at onset of schizophrenia
TRE Barnes et al.
BRITISH JOURNAL OF PSYCHIATRY (2006)
A 12-week, randomized, open-label, parallel-group trial of topiramate in limiting weight gain during olanzapine treatment in patients with schizophrenia
JH Kim et al.
SCHIZOPHRENIA RESEARCH (2006)
An exploratory open-label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia
DC Henderson et al.
ACTA PSYCHIATRICA SCANDINAVICA (2006)
JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice
D Wood et al.
HEART (2005)
Physical activity patterns in adults with severe mental illness
GL Daumit et al.
JOURNAL OF NERVOUS AND MENTAL DISEASE (2005)
Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine
KA Graham et al.
AMERICAN JOURNAL OF PSYCHIATRY (2005)
Topiramate add-on in treatment-resistant schizophrenia:: A randomized, double-blind, placebo-controlled, crossover trial
J Tiihonen et al.
JOURNAL OF CLINICAL PSYCHIATRY (2005)
Topiramate as an adjuvant treatment with atypical antipsychotics in schizophrenic patients experiencing weight gain
YH Ko et al.
CLINICAL NEUROPHARMACOLOGY (2005)
Research on adverse drug events.: I.: Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes
JS Silvestre et al.
METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY (2005)
Influence of topiramate on olanzapine-related adiposity in women - A random, double-blind, placebo-controlled study
MK Nickel et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders
BJ Kinon et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets - Role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia
DE Johnson et al.
DIABETES (2005)
Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents - A frequently sampled intravenous glucose tolerance test and minimal model analysis
DC Henderson et al.
ARCHIVES OF GENERAL PSYCHIATRY (2005)
Amantadine for weight gain associated with olanzapine treatment
W Deberdt et al.
EUROPEAN NEUROPSYCHOPHARMACOLOGY (2005)
Surgical treatment of morbid obesity in schizophrenic patients
N Hamoui et al.
OBESITY SURGERY (2004)
Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients
B Arranz et al.
JOURNAL OF CLINICAL PSYCHIATRY (2004)
Dietary sugar and polyunsaturated fatty acid consumption as predictors of severity of schizophrenia symptoms
C Stokes et al.
NUTRITIONAL NEUROSCIENCE (2004)
Effects of antipsychotics on fat deposition and changes in leptin and insulin levels - Magnetic resonance imaging study of previously untreated people with schizophrenia
ZJ Zhang et al.
BRITISH JOURNAL OF PSYCHIATRY (2004)
Obesity as a risk factor for antipsychotic noncompliance
PJ Weiden et al.
SCHIZOPHRENIA RESEARCH (2004)
Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia
MCM Ryan et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study
M Poyurovsky et al.
AMERICAN JOURNAL OF PSYCHIATRY (2003)
Diet, smoking and cardiovascular risk in people with schizophrenia - Descriptive study
RG McCreadie
BRITISH JOURNAL OF PSYCHIATRY (2003)
Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia
JW Newcomer et al.
ARCHIVES OF GENERAL PSYCHIATRY (2002)
The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy
E Hilger et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2002)
No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites
E Spina et al.
THERAPEUTIC DRUG MONITORING (2001)
Smoking as a modifiable risk factor for type 2 diabetes in middle-aged men
SG Wannamethee et al.
DIABETES CARE (2001)
Postmarketing experience with topiramate and cognition
WO Tatum et al.
EPILEPSIA (2001)
Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline
WKH Fakhoury et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2001)
Effects of topiramate on cognitive function
PJ Thompson et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2000)
Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia
CR Breese et al.
NEUROPSYCHOPHARMACOLOGY (2000)
Diabetes prevalence and socioeconomic status: a population based study showing increased prevalence of type 2 diabetes mellitus in deprived areas
V Connolly et al.
JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH (2000)
Share Paper
